Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Report Date: November 6, 2025
Reporting Period: Third Quarter ended September 30, 2025
Context: The filing announces the company's financial results for the third quarter of 2025 and provides a corporate update. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text serves as a cover document and does not contain specific numerical data. The filing explicitly states that the financial results are detailed in the attached press release (Exhibit 99.1), which is not included in the input text. Consequently, the following metrics are not available in the source data:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not disclose specific material changes in financial performance or operations compared to the prior comparable period. It only confirms that an announcement regarding the third quarter results was made on November 6, 2025.
Guidance, Outlook, and Risks
Management Commentary: The company provided a "corporate update" alongside the financial results, but the specific content of this update is not present in the 8-K text.
Guidance and Outlook: No forward-looking guidance or outlook figures are included in the provided text.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability. No specific new risks or contingencies are detailed in the text.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) to obtain actual revenue, net loss, and cash burn figures for Q3 2025.
- Verify the specific details of the "corporate update" mentioned in the filing, as these are not in the 8-K text.
- Check for any updated clinical trial milestones or regulatory status changes referenced in the full press release.
- Confirm the company's cash runway and liquidity position as of September 30, 2025, from the full financial tables.